
Drugs IPOs Depend o...


| WOLF | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| 128.28 | 188.93 | 117.50 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 4.40 | 0.21 | 0.06 |
| Net Income | -0.21 | 0.00 | |
| EPS | -0.38 | 0.00 |
| EBITDA | 76.91M |
| REVENUE | 296.71M |
| Qtr (03/12) | Qtr (06/12) | FY (12/12) | FY (12/13) | |
|---|---|---|---|---|
| Average Estimate | $-0.14 | $-0.07 | $-0.42 | $-0.22 |
| Number of Analysts | 2 | 2 | 3 | 2 |
| High Estimate | $-0.12 | $-0.06 | $-0.29 | $-0.10 |
| Low Estimate | $-0.17 | $-0.08 | $-0.50 | $-0.33 |
| Prior Year | $-0.47 | $-0.22 | $-0.54 | $-0.42 |
| Growth Rate (Year over Year) | 69.15% | 68.18% | 21.60% | 49.21% |